Investors continue to show interest in the medical possibilities of cannabis-derived cannabidiol, or CBD, eagerly watching Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) as it begins patient trials on a CBD-infused skin gel aimed at treating Fragile X syndrome.
Canaccord Genuity reiterated a bullish stance on the stock Thursday after meeting with Zynerba CEO Armando Anido.
Sumant Kulkarni reiterated a Buy rating on Zynerba with an $18 price target.
Need more cannabis news? Check out all of our coverage here.
“We believe the stock presents a significant opportunity for risk-tolerant investors,” Kulkarni said in the note. (See his track record here.)
The 14-week trial for the Fragile X transdermal skin gel, Zygel, is on track for a data readout in the second half of 2019, the analyst said.
If the results show some success, Zynerba hopes to gain approval in 2021.
Canaccord Genuity is modeling a 50% probability of approval for the FXS treatment.
The company is also expecting open-label data on the use of the drug for developmental and epileptic encephalopathies in the third quarter of 2019, but the trial for Fragile X treatment is the bigger inflection point, Kulkarni said.
Zynerba shares were up 3.07% on Friday morning to $13.30.
Zynerba Advances Cannabidiol Treatment With New Patent Win
FDA Public Hearing About CBDs Prescribes Caution, Bearishness, and Deliberation
Photo courtesy of Zynerba.
Latest Ratings for ZYNE
|Apr 2019||Initiates Coverage On||Buy|
|Sep 2018||Initiates Coverage On||Overweight|
View More Analyst Ratings for ZYNE
View the Latest Analyst Ratings
See more from Benzinga
- Twitter Won't Block Rule-Breaking Tweets From Public Figures, But Will Warn You
- Analyst: Boeing 737 MAX Still On Path To Take Flight Again In 6-9 Months
- SunTrust Is Bullish On Take-Two Thanks To Strong Video Game Pipeline
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.